News – Circle Pharma

Background Publications on Macrocycles

Our Science

The Promise of Macrocycles

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut. labore et dolore magnam aliquam quaerat voluptatem.

Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

July 1, 2024

Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference

October 23, 2023

Novel orally bioavailable macrocycles that target cyclin A and B elicit antitumor activity in breast cancer patient-derived xenograft models

October 23, 2023

Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 9, 2023

Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development

July 26, 2023

Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B

July 19, 2023

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

April 19, 2023

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

April 19, 2023

Circle Pharma appoints Stephen Kelsey, MB ChB, MD, to its board of directors

December 15, 2022

Background Publications on Macrocycles

The Promise of Macrocycles

Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference

Novel orally bioavailable macrocycles that target cyclin A and B elicit antitumor activity in breast cancer patient-derived xenograft models

Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development

Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

Circle Pharma appoints Stephen Kelsey, MB ChB, MD, to its board of directors

Sign up to stay informed

About Us

Our Science

What’s New

Work With Us

Contact Us